View Older Stories View More Recent Stories

Nov 20, 2024 08:00AM Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
Nov 13, 2024 08:00AM Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
Nov 12, 2024 07:54AM Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Nov 4, 2024 04:05PM Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Oct 10, 2024 07:00AM Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Oct 3, 2024 08:00AM Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Sep 3, 2024 07:02AM Foghorn Therapeutics Inc. (FHTX) Appoints Anna Rivkin as Chief Business Officer
Sep 3, 2024 07:00AM Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Aug 8, 2024 07:00AM Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
Jul 25, 2024 08:00AM Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World
Jul 23, 2024 06:00AM Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
May 28, 2024 07:00AM Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 22, 2024 06:21PM Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 6, 2024 07:00AM Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Apr 16, 2024 07:01AM Foghorn Therapeutics (FHTX) Announces Appointment of Kristian Humer as Chief Financial Officer
Apr 16, 2024 07:00AM Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Apr 9, 2024 04:30PM Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Apr 8, 2024 08:00AM Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Apr 5, 2024 07:00AM Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Mar 26, 2024 07:00AM Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Mar 7, 2024 07:00AM Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
Mar 5, 2024 04:48PM Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-90
Feb 28, 2024 07:00AM Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
Feb 8, 2024 07:00AM Foghorn Therapeutics (FHTX) Provides Pipeline Update on FHD-909
Feb 8, 2024 07:00AM Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
Jan 8, 2024 07:00AM Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
Jan 5, 2024 10:00AM Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
Jan 3, 2024 04:07PM Foghorn Therapeutics Inc. (FHTX) Announces CFO Departure
Jan 3, 2024 04:05PM Foghorn Therapeutics Announces CFO Departure
Dec 1, 2023 07:00AM Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hemat
Nov 2, 2023 07:00AM Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
Nov 1, 2023 10:30AM Flagship Pioneering Launches Pioneering Intelligence
Oct 24, 2023 08:00AM Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
Oct 13, 2023 08:00AM Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
Oct 4, 2023 08:00AM Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
Sep 5, 2023 08:00AM Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Aug 31, 2023 07:00AM Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
Aug 29, 2023 09:00AM Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
Aug 8, 2023 07:02AM Foghorn Therapeutics (FHTX) Announces Chief Medical Officer Succession
Aug 8, 2023 07:00AM Foghorn Therapeutics Announces Chief Medical Officer Succession
Aug 4, 2023 07:00AM Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
Jun 28, 2023 07:00AM Foghorn Therapeutics (FHTX) Reports Clinical Data from Phase 1 Study of FHD-286
Jun 28, 2023 07:00AM Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
Jun 7, 2023 08:00AM Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Jun 5, 2023 07:00AM Foghorn Therapeutics (FHTX) Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286
Jun 5, 2023 07:00AM Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
May 16, 2023 06:00AM Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
May 8, 2023 07:00AM Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
Apr 25, 2023 04:05PM Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
Apr 25, 2023 04:05PM Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
View More Recent Stories View Older Stories